Literature DB >> 17462790

A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.

Li Liu1, Jui-Hung Yen, Doina Ganea.   

Abstract

Vasoactive intestinal peptide (VIP) is a potent anti-inflammatory agent. In addition to the deactivation of macrophages, dendritic cells, and microglia, VIP shifts the Th1/Th2 balance, promoting the preferential differentiation and survival of Th2 cells, to the detriment of the proinflammatory Th1 effectors. Several mechanisms operate in the Th1/Th2 shift induced by VIP. Here we report on a novel mechanism for the effect of VIP on T cell differentiation, and show that VIP inhibits Th1 differentiation by interfering directly with the IL-12Jak2/STAT4 signaling pathway in T cells. The effect of VIP is cAMP-dependent, and appears to be mediated through the activation of protein tyrosine phosphatases (PTP), with SHP-2 as a potential target. The activation of PTPs represents a novel cAMP-downstream target for the immunomodulatory effects of VIP.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17462790      PMCID： PMC2093951          DOI： 10.1016/j.peptides.2007.03.015

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  36 in total

1.  Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy.

Authors:  F Hong; V A Nguyen; B Gao
Journal:  FASEB J       Date:  2001-07       Impact factor: 5.191

Review 2.  Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response.

Authors:  Cheng-Kui Qu
Journal:  Biochim Biophys Acta       Date:  2002-11-11

3.  Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling.

Authors:  Ryuta Nishikomori; Takashi Usui; Chang-Yu Wu; Akio Morinobu; John J O'Shea; Warren Strober
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

4.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.

Authors:  M Delgado; D Ganea
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

5.  Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor.

Authors:  J K Voice; G Dorsam; H Lee; Y Kong; E J Goetzl
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

6.  Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

Authors:  E J Goetzl; J K Voice; S Shen; G Dorsam; Y Kong; K M West; C F Morrison; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

7.  Adrenocorticotrophic hormone stimulates phosphotyrosine phosphatase SHP2 in bovine adrenocortical cells: phosphorylation and activation by cAMP-dependent protein kinase.

Authors:  S Rocchi; I Gaillard; E van Obberghen; E M Chambaz; I Vilgrain
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

8.  Association of neuropeptides with Th1/Th2 balance and allergic sensitization in children.

Authors:  G Herberth; C Daegelmann; A Weber; S Röder; T Giese; U Krämer; R P F Schins; H Behrendt; M Borte; I Lehmann
Journal:  Clin Exp Allergy       Date:  2006-11       Impact factor: 5.018

9.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells.

Authors:  Mario Delgado; Javier Leceta; Doina Ganea
Journal:  FASEB J       Date:  2002-09-05       Impact factor: 5.191

Review 10.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.

Authors:  Doina Ganea; Mario Delgado
Journal:  Crit Rev Oral Biol Med       Date:  2002
View more
  6 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

2.  Elevated Cyclic AMP Inhibits Mycobacterium tuberculosis-Stimulated T-cell IFN-γ Secretion Through Type I Protein Kinase A.

Authors:  Yoon-Tae Chung; Virginia Pasquinelli; Javier O Jurado; Xisheng Wang; Na Yi; Peter F Barnes; Veronica E Garcia; Buka Samten
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

Review 3.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.

Authors:  D Ganea; K M Hooper; W Kong
Journal:  Acta Physiol (Oxf)       Date:  2014-12-11       Impact factor: 6.311

4.  Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses.

Authors:  Jihyung Lee; Junyan Zhang; Young-Jun Chung; Jun Hwan Kim; Chae Min Kook; José M González-Navajas; David S Herdman; Bernd Nürnberg; Paul A Insel; Maripat Corr; Ji-Hun Mo; Ailin Tao; Kei Yasuda; Ian R Rifkin; David H Broide; Roger Sciammas; Nicholas Jg Webster; Eyal Raz
Journal:  Elife       Date:  2020-02-04       Impact factor: 8.140

5.  Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP-VPAC2 signalling pathway.

Authors:  Muhua Huang; Jinfeng Wu; Jingcheng Dong
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 6.  Regulatory Peptides in Asthma.

Authors:  Katarzyna Kaczyńska; Dominika Zając; Piotr Wojciechowski; Monika Jampolska
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.